Caffeic Acid Combining High-dose Dexamethasone in Management of ITP

Inclusion Criteria:

• 1.Meet the diagnostic criteria for immune thrombocytopenia; 2.Untreated hospitalizedpatients, may be male or female, between the ages of 18 ~ 80 years; 3.To show aplatelet count <30 * 10^9/L, and with bleeding manifestations; 4.Willing and able tosign written informed consent

Exclusion Criteria:

• 1.Received chemotherapy or anticoagulants or other drugs affecting the platelet countswithin 3 months before the screening visit 2.Received second-line ITP-specifictreatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc)within 3 months before the screening visit 3.Received high-dose steroids or IVIG inthe 3 weeks prior to the start of the study 4.Current HIV infection or hepatitis Bvirus or hepatitis C virus infections 5.Severe medical condition (lung, hepatic orrenal disorder) other than chronic ITP. Unstable or uncontrolled disease or conditionrelated to or impacting cardiac function (e.g., unstable angina, congestive heartfailure, uncontrolled hypertension or cardiac arrhythmia) 6.Female patients who arenursing or pregnant, who may be pregnant, or who contemplate pregnancy during thestudy period 7.Have a known diagnosis of other autoimmune diseases, established in themedical history and laboratory findings with positive results for the determination ofantinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or directCoombs test 8.Patients who are deemed unsuitable for the study by the investigator